Abstract

Objective Implantable cardioverter defibrillators (ICDs) are routinely used to prevent sudden cardiac death (SCD) in selected hypertrophic cardiomyopathy (HCM) patients, but the determinants of device-related complications, therapies and long-term cardiovascular mortality in ICD recipients are not known.

Conclusions HCM patients with an ICD have a significant cardiovascular mortality and are exposed to frequent inappropriate shocks and implant complications. These data suggest that new strategies are required to improve patient selection for ICDs and to prevent disease progression in those that receive a device.

Footnotes

Funding This research was supported by grants from the Spanish Society of Cardiology (to Dr Cardona), European Society of Cardiology (to Dr Calcagnino and Dr Quarta) and Hellenic Society of Cardiology (to Dr Tsovolas). This work was undertaken at The Heart Hospital (University College London Hospitals NHS trust)/University College London, which received a proportion of funding from the Department of Health's National Institute for Health Research (NIHR) London Biomedical Research Centres funding scheme.

Competing interests Dr Lambiase received support from St Jude, and Dr Elliott received fees from Medtronic. All other authors have no potential conflicts of interest to declare.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.